Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Paclitaxel/Carboplatin Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma.

Next Previous
X
Search
Trial Profile

Phase III Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Paclitaxel/Carboplatin Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary) ; Carboplatin; Paclitaxel
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer; Onyx Pharmaceuticals

    • Most Recent Events

    • 07 Jul 2009 Actual end date (1 Jan 2009) added as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Actual end date (1 Jan 2009) added as reported by ClinicalTrials.gov.
    • 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry, record no. ACTRN12605000684628).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top